文献速递临床试验与 GCP真实世界研究与卫生经济

腹主动脉瘤破裂:腔内策略与开放修复的三年临床及成本效果

Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial.
PubMed 文献 · BMJ · 2017-11-14

IMPROVE随机试验比较疑诊破裂腹主动脉瘤的腔内策略(适合者腔内、不适合者开放)与开放修复。共613例患者随机,316例腔内策略、297例开放修复。三年时腔内策略组死亡率低于开放修复组(48% v 56%),QALYs增加0.17,平均费用低2605英镑,成本效果概率>90%。

要点

  • 三年死亡率腔内策略组48% vs 开放修复组56%,死亡风险比HR 0.57。
  • 修复破裂的502例中三年死亡率腔内策略组42% vs 开放组54%,OR 0.62。
  • 七年时两组死亡率均约60%,HR 0.92,无显著差异。

核心结论

  • 三年时,与开放修复相比,疑诊破裂腹主动脉瘤的腔内策略与生存获益、QALYs增加、再干预率相似及费用降低相关,且具有成本效果。

研究设计与样本

  • 随机对照试验,纳入30个血管中心(英国29个、加拿大1个),2009-16年,613例临床诊断破裂动脉瘤患者(480例男性),其中502例接受急诊修复。

主要发现

  • 随机分组中,腔内策略组316例(275例确认破裂),开放修复组297例(261例确认破裂)。
  • 90天死亡率相似;3个月至3年期间腔内策略组死亡少于开放修复组(HR 0.57,95%CI 0.36-0.90),三年死亡率48% v 56%。
  • 七年时两组死亡率均约60%(HR 0.92,95%CI 0.75-1.13)。
  • 修复破裂的502例中,三年死亡率腔内策略组42% v 开放组54%(OR 0.62,95%CI 0.43-0.88),七年时无 clear 差异(HR 0.86,95%CI 0.68-1.08)。
  • 三年内再干预率无显著差异(HR 1.02,95%CI 0.79-1.32);两组早期再干预率快,中期明显减慢。

关键数值与推荐

  • 三年QALYs增益0.17(95%CI 0.00-0.33)。
  • 腔内策略组住院天数更少,平均费用低2605英镑(95%CI -5966至702英镑)。
  • 在所有支付意愿水平下,腔内策略具有成本效果的概率>90%。

临床怎么用

  • 研究结果支持增加使用腔内策略,并扩大急诊腔内修复的可及性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To assess the three year clinical outcomes and cost effectiveness of a strategy of endovascular repair (if aortic morphology is suitable, open repair if not) versus open repair for patients with suspected ruptured abdominal aortic aneurysm.Design Randomised controlled trial.Setting 30 vascular centres (29 in UK, one in Canada), 2009-16.Participants 613 eligible patients (480 men) with a clinical diagnosis of ruptured aneurysm, of whom 502 underwent emergency repair for rupture.Interventions 316 patients were randomised to an endovascular strategy (275 with confirmed rupture) and 297 to open repair (261 with confirmed rupture).Main outcome measures Mortality, with reinterventions after aneurysm repair, quality of life, and hospital costs to three years as secondary measures.Results The maximum follow-up for mortality was 7.1 years, with two patients in each group lost to follow-up by three years. After similar mortality by 90 days, in the mid-term (three months to three years) there were fewer deaths in the endovascular than the open repair group (hazard ratio 0.57, 95% confidence interval 0.36 to 0.90), leading to lower mortality at three years (48% v 56%), but by seven years mortality was about 60% in each group (hazard ratio 0.92, 0.75 to 1.13). Results for the 502 patients with repaired ruptures were more pronounced: three year mortality was lower in the endovascular strategy group (42% v 54%; odds ratio 0.62, 0.43 to 0.88), but after seven years there was no clear difference between the groups (hazard ratio 0.86, 0.68 to 1.08). Reintervention rates up to three years were not significantly different between the randomised groups (hazard ratio 1.02, 0.79 to 1.32); the initial rapid rate of reinterventions was followed by a much slower mid-term reintervention rate in both groups. The early higher average quality of life in the endovascular strategy versus open repair group, coupled with the lower mortality at three years, led to a gain in average quality adjusted life years (QALYs) at three years of 0.17 (95% confidence interval 0.00 to 0.33). The endovascular strategy group spent fewer days in hospital and had lower average costs of -£2605 (95% confidence interval -£5966 to £702) (about €2813; $3439). The probability that the endovascular strategy is cost effective was >90% at all levels of willingness to pay for a QALY gain.Conclusions At three years, compared with open repair, an endovascular strategy for suspected ruptured abdominal aortic aneurysm was associated with a survival advantage, a gain in QALYs, similar levels of reintervention, and reduced costs, and this strategy was cost effective. These findings support the increasing use of an endovascular strategy, with wider availability of emergency endovascular repair.Trial registration Current Controlled Trials ISRCTN48334791; ClinicalTrials NCT00746122.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial. BMJ. 2017. PMID: 29138135. doi:10.1136/bmj.j4859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。